Compare COMM & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COMM | ARQT |
|---|---|---|
| Founded | 1976 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.3B |
| IPO Year | 2013 | 2020 |
| Metric | COMM | ARQT |
|---|---|---|
| Price | $17.95 | $27.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $13.25 | ★ $24.83 |
| AVG Volume (30 Days) | ★ 4.7M | 2.1M |
| Earning Date | 10-30-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.52 | N/A |
| Revenue | ★ $5,299,100,000.00 | $317,929,000.00 |
| Revenue This Year | $37.00 | $85.51 |
| Revenue Next Year | $7.36 | $30.74 |
| P/E Ratio | $5.05 | ★ N/A |
| Revenue Growth | 33.82 | ★ 129.21 |
| 52 Week Low | $2.94 | $11.13 |
| 52 Week High | $20.55 | $31.77 |
| Indicator | COMM | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 47.41 |
| Support Level | $17.62 | $28.30 |
| Resistance Level | $20.61 | $31.77 |
| Average True Range (ATR) | 0.77 | 1.14 |
| MACD | -0.30 | -0.57 |
| Stochastic Oscillator | 11.02 | 5.80 |
CommScope Holding Co Inc is a provider of infrastructure solutions for communication, data center, and entertainment networks. The company provides solutions for wired and wireless networks to enable service providers, including cable, telephone, data center, and digital broadcast satellite operators and media programmers, to deliver media, voice, Internet Protocol (IP) data services, and Wi-Fi to their subscribers and allow enterprises to experience constant wireless and wired connectivity across complex and varied networking environments. The company's operating segments are: Connectivity and Cable Solutions (CCS), Networking, Intelligent Cellular and Security Solutions (NICS), and Access Network Solutions (ANS).
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.